Polatuzumab Biosimilar Antibody-Drug Conjugate (CD79B) for Research
Pre-Made Polatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for biological drug disovery items including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Polatuzumab vedotin contains a monoclonal antibody that binds to a protein called CD79B, which is found on B cells (a type of white blood cell) and some lymphoma cells. It also contains an anticancer drug, which may help kill cancer cells. Polatuzumab vedotin is a type of antibody-drug conjugate. Also called Polivy.
Order Information
| Catalog No. | Package | Price(In USD) |
|---|---|---|
| GMP-Bios-ab-449-1mg | 1mg | 243 |
| GMP-Bios-ab-449-10mg | 10mg | |
| GMP-Bios-ab-449-100mg | 100mg | |
| GMP-Bios-ab-449-xmg | >100mg |
Product Details
| Products Name (INN Index) | Pre-Made Polatuzumab biosimilar, Whole mAb ADC, Anti-CD79B Antibody: Anti-AGM6/B29/IGB therapeutic antibody |
| INN Name | Polatuzumab |
| Target | CD79B |
| Format | Whole mAb ADC |
| Derivation | |
| Species Reactivity | Human |
| CH1 Isotype | IgG1 |
| VD LC | Kappa |
| Highest_Clin_Trial (Jan '20) | Approved |
| Est. Status | Active |
| 100% SI Structure | None |
| 99% SI Structure | None |
| 95-98% SI Structure | None |
| Year Proposed | 2012 |
| Year Recommended | 2013 |
| Companies | Chugai Pharmaceutical;Genentech;Roche |
| Conditions Approved | Diffuse large B cell lymphoma |
| Conditions Active | Non-Hodgkin's lymphoma;Follicular lymphoma |
| Conditions Discontinued | Chronic lymphocytic leukaemia |
| Development Tech | na |
About target - CD79B
1. Protein B-cell antigen receptor complex-associated protein beta chain
2. Gene CD79B
3. Organism Homo sapiens (Human)
Function
SRequired in cooperation with CD79A for initiation of the signal transduction cascade activated by the B-cell antigen receptor complex (BCR) which leads to internalization of the complex, trafficking to late endosomes and antigen presentation. Enhances phosphorylation of CD79A, possibly by recruiting kinases which phosphorylate CD79A or by recruiting proteins which bind to CD79A and protect it from dephosphorylation.

